HC Wainwright Issues Negative Outlook for Biohaven Earnings

Key Points

• HC Wainwright lowered Biohaven’s Q3 2026 EPS estimate to a loss of $0.86 from $0.84 and maintained a Neutral rating with a $10 price target. The firm projects continued losses through 2029, including $3.44 per share for fiscal 2026.
• Biohaven reported a Q2 loss of $0.91 per share, missing the consensus estimate of a $0.76 loss by $0.15.
• Analyst sentiment remains mixed but leans positive, with a consensus “Moderate Buy” rating and an average price target of $21.75, while shares recently opened at $13.91.

Biohaven Ltd. (NYSE:BHVN - Free Report) - Stock analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for Biohaven in a note issued to investors on Wednesday, August 12th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.86) for the quarter, down from their previous forecast of ($0.84). HC Wainwright has a "Neutral" rating and a $10.00 price objective on the stock. The consensus estimate for Biohaven's current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Biohaven's Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($3.44) EPS, FY2027 earnings at ($3.05) EPS, FY2028 earnings at ($2.41) EPS and FY2029 earnings at ($1.41) EPS.

Biohaven (NYSE:BHVN - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.15).

BHVN has been the subject of several other research reports. Bank of America restated an "underperform" rating and issued a $11.00 target price (down from $12.00) on shares of Biohaven in a research report on Monday, June 29th. Royal Bank Of Canada boosted their price objective on Biohaven from $22.00 to $23.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 11th. Raymond James Financial reiterated a "strong-buy" rating on shares of Biohaven in a research report on Wednesday, May 27th. Wall Street Zen raised Biohaven from a "strong sell" rating to a "sell" rating in a report on Saturday, June 27th. Finally, Morgan Stanley raised their target price on Biohaven from $18.00 to $19.00 and gave the company an "overweight" rating in a research report on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, Biohaven presently has an average rating of "Moderate Buy" and an average price target of $21.75.

Biohaven Trading Up 0.4%

Shares of NYSE:BHVN opened at $13.91 on Monday. The company has a market cap of $2.10 billion, a PE ratio of -3.00 and a beta of 1.26. The company's 50-day moving average price is $14.59 and its 200 day moving average price is $11.74. Biohaven has a fifty-two week low of $7.48 and a fifty-two week high of $18.57. The company has a quick ratio of 4.73, a current ratio of 4.73 and a debt-to-equity ratio of 21.23.

Institutional Trading of Biohaven

Hedge funds and other institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC grew its position in Biohaven by 1,145.9% in the first quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company's stock worth $148,214,000 after buying an additional 16,127,247 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of Biohaven during the 2nd quarter valued at $196,574,000. Jupiter Topco LLC acquired a new stake in shares of Biohaven during the 2nd quarter valued at $127,852,000. Suvretta Capital Management LLC boosted its stake in shares of Biohaven by 83.0% during the 4th quarter. Suvretta Capital Management LLC now owns 10,286,937 shares of the company's stock worth $116,140,000 after acquiring an additional 4,666,666 shares in the last quarter. Finally, Infinitum Asset Management LLC boosted its stake in shares of Biohaven by 267.6% during the 4th quarter. Infinitum Asset Management LLC now owns 6,250,000 shares of the company's stock worth $70,562,000 after acquiring an additional 4,550,000 shares in the last quarter. 88.78% of the stock is currently owned by institutional investors.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company's most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source